GENE ONLINE|News &
Opinion
Blog

2020-06-28| COVID-19R&D

COVID-19: Discovery of New Spike Protein Neutralizing Antibody Reveals Promising Drug Target

by Sahana Shankar
Share To

By Sahana Shankar, Ph.D. Candidate

As opposed to antibodies that bind to the receptor-binding domain, scientists discover a new antibody that binds to the N-Terminal Domain of the SARS-CoV-2’s spike protein, potentially uncovering a novel drug target.

While the global COVID-19 vaccine efforts are advancing at full throttle, data from recovering patients have facilitated the development of ancillary treatments such as convalescent plasma, neutralizing antibodies, and repurposed drugs such as remdesivir and dexamethasone. Many clinicians have expressed optimism about the use of neutralizing antibodies as an interim measure while we await the vaccine.

It is now established that the COVID-19 causing SARS-CoV-2 uses its spike (S) protein to gain cellular entry. The cell surface protein is composed of 2 subunits, S1, and S2, both of which constitute the extracellular domain (ECD). While the N-terminal domain (NTD) and the receptor-binding domain (RBD) of S1 enable receptor binding, S2 mediates membrane fusion to deliver viral RNA into the host. At present, the conventionally accepted pathway of SARS-CoV-2 infection is via the binding of RBD to the ACE2 receptor on host cells. However, new reports have also suggested a secondary pathway via the NRP1 receptor.

The immune system of recovering patients identifies different parts of the viral proteins as antigens and develops antibodies against them. The neutralizing ability can vary between individuals based upon the specific antigens the antibodies target. Since they exert an effective and specific antiviral response, they can be isolated and characterized to develop therapeutics. Quite a few studies have focused on neutralizing antibodies against the RBD. However, results suggest that a cocktail of antibodies targeting different viral proteins would be more robust and effective for viral clearance.

In a new collaborative study published in Science, scientists from Beijing report the high neutralization potency of a monoclonal antibody against the NTD of the S protein. Plasma and peripheral blood mononuclear cells (PBMCs) of ten recovered Chinese patients were evaluated for their binding affinity to the nucleocapsid (N) protein and the ECD, S1, S2, and RBD domains of the S protein. Plasma antibodies from nine patients were able to bind all five protein fragments, and the remaining one was able to bind to ECD and S2 domains. These Abs were able to neutralize HIV-vectored SARS-CoV-2 pseudovirus and authentic SARS-CoV-2 in Vero6 cells, demonstrating their ability to elicit an immune response against SARS-CoV-2.

Of the 399 monoclonal Abs (mAbs) isolated by sorting IgG+ memory B cells and plasma B cells, the team screened for S protein-specific antibodies and classified them into four groups based on EC50 values by ELISA.

Group Antigen Subgroup
1 S-ECD
2 S-ECD+S1 2A- S-ECD+S1

2B- S-ECD+S1+RBD3S1+S24S-ECD+S2

With a competition-binding assay, they screened for overlapping antigenic sites shared between mAbs from different groups and found that there was a significant diversity in the epitopes recognized, indicating that the SARS-CoV-2 infection induces a wide range of antibody responses.

To further characterize the activity, they performed neutralization studies on 35 mAbs against S-ECD and found three candidates with high to medium neutralizing capacity. Interestingly, antibodies against RBD did not have high inhibitory activity. With real-time qPCR, cytopathic effect assay, and luciferase reporter assays, the investigators confirmed their antiviral activity. Interestingly, two of them were able to protect ACE2-293T cells from SARS-CoV-2 pseudovirus but were not effective against the authentic SARS-CoV-2 virus. Thus, 4A8 mAb emerged as a potent antibody against SARS-CoV-2 and provided a potential drug candidate.

To further understand the binding mechanism, the protein complex was subjected to structural studies. In concordance with previous reports, the cryo-EM structure at 3.1Å showed that the trimeric S protein has two asymmetric conformations, two of the three RBDs in ‘down’ conformation and one in ‘up’ conformation. The trimeric S protein was bound to 3 4A8 Fab chains by its NTD. However, irrespective of the up/down conformations, the binding interface between the NTD and 4A8 was identical. Besides, the 4A8 binding stabilized the NTD and improved the structural model by identifying five new loops, adding more information. Thanks to the high resolution, specific residues promoting the interactions between the antibody chains, and helical regions of the NTD were identified.

The distinguishing feature of the study is that the majority of mAbs did not recognize the RBD of the spike protein, which is thought to be the most promising drug target. Remarkably, these mAbs did not prevent S protein binding to ACE2, indicating there are other mechanisms to block viral entry. In conclusion, the study proposes that the NTD of the S protein may be a vulnerable epitope and may be a suitable candidate for a structure-based vaccine. The 4A8 mAb could lead to an ‘antibody cocktail,’ which could further enhance the antiviral activity against SARS-CoV-2.

Editor: Rajaneesh K. Gopinath, Ph.D.

Related Article: Dexamethasone Renews Hopes for a Life Saving COVID-19 Treatment

References
  1. https://science.sciencemag.org/content/early/2020/06/19/science.abc6952

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
Global Expansion between Europe and India of Novel anti-PD-1 mAb Serplulimab
2023-10-31
LATEST
2024 Nobel Prize in Medicine: Uncovering the Secrets of microRNA in Gene Regulation
2024-10-08
Sciwind Biosciences Announces Oral Presentation on Oral GLP-2 Research Progress at the 32nd United European Gastroenterology Week (UEG Week 2024)
2024-10-07
Bio Japan 2024 and Medical Japan 2024 Unleashing Innovation in Biopharmaceuticals and Healthcare Technologies
2024-10-07
Starboard Value Takes $1 Billion Stake in Pfizer, Eyes Major Overhaul
2024-10-07
Generative AI Makes its Debut in Smart Healthcare with NVIDIA Experts at the Helm
2024-10-04
How TCELS is Moving Thailand’s Biotech Industries From Local to Global
2024-10-04
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
EVENT
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
2024-10-28
BioFuture 2024
New York, U.S.A.
2024-10-30
AusBiotech 2024
Melbourne, Australia
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top